Truncated EGF receptor

Details Truncated EGF receptor Truncated EGF receptor

2005-08-22

2008-11-11

Spector, Lorraine (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Chemical modification or the reaction product thereof, e.g.,...

C530S350000, C530S387100, C514S012200

Reexamination Certificate

active

07449559

ABSTRACT:
The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.

REFERENCES:
patent: 5218090 (1993-06-01), Conners
patent: 5708156 (1998-01-01), Ilekis
patent: 6696290 (2004-02-01), Fitspatrick et al.
patent: 2002/0002276 (2002-01-01), Fitzpatrick et al.
patent: 2003/0190702 (2003-10-01), Maile et al.
patent: WO 91/03489 (1991-03-01), None
patent: WO 9919488 (1999-04-01), None
patent: WO 99/62955 (1999-12-01), None
Zhou et al., ErbB-4: a receptor tyrosine kinase, Inflamm. Res. 51:091-101, 2002.
Junttila et al., ErbB4 and its isoforms: Selective regulation of growth factor responses by naturally occurring receptor variants, TCM 10(7): 304-310, 2000.
Jorissen te al., Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor, Protein Sci., 9: 310-324, 2000.
Riese te al., The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to neu, ErbB-3, and ErbB-4, J. Biol. Chem. 271(16): 20047-20052, Aug. 16, 1996.
Ashkenazi et al. (1997) “Immunoadhesins as Research Tools and Therapeutic Agents,”Curr. Opin. Immunol. 9:195-200.
Bajaj et al. (1987) “On the Tertiary Structure of the Extracellular Domains of the Epidermal Growth Factor and Insulin Receptors,”Biochim. Biophys. Acta. 916:220-226.
Bishayee et al. (2000) “Role of Conformational Alteration in The Epidermal Growth Factor Receptor (EFGFR) Function,”Biochem. Pharmacol. 60:1217-1223.
Burgess et al. (1994) “Growth Factors and Their Receptors: New Opportunities for Cancer Treatment,”Pathology26:453-463.
Carter, P. (1987) “Improved Oligonucleotide-Directed Mutagenesis Using M13 Vectors,”Methods Enzymol154:382-403.
Catimel et al. (1999) “Recent Applications of Instrumental Biosensors for Protein and Peptide Structure-Function Studies,”Protein Pep. Lett. 6:319-340.
Catimel et al. (1997) “Kinetic Analysis of the Interaction Between the Monoclonal Antibody A33 and its Colonic Epithelial Antigen by the Use of an Optical Biosensor,”J. Chromatogr. 776:15-30.
De Crescenzo et al. (2000) “Real-Time Kinetic Studies on the Interaction of Transforming Growth Factor α With the Epidermal Growth Factor Receptor Extracellular Domain Reveal a Conformational Change Model,”Biochem. 39:9466-9476.
Domagala et al. (2000) “Stoichiometry, Kinetic and Binding Analysis of the Interaction Between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor,”Growth Factors18:11-29.
Ekstrand et al. (1992) “Amplified and Rearranged Epidermal Growth Factor Receptor Genes in Human Gliblastomas Reveal Deletions or Sequences Encoding Portions of the N- and/or C-Terminal Tails,”Proc. Natl. Acad. Sci. USA89:4309-4313.
Elleman et al. (2001) “Identification of a Determinant of Epidermal Growth Factor Receptor Ligand-Binding Specificity Using a Truncated, High-Affinity Form of the Ectodomain,”Biochem. 40(30):8930-8939.
Fitzpatrick et al. (1999) “Formation of High Affinity Heregulin Binding Site Using the Soluble Extracellular Domains of ErbB2 with ErbB3 or ErbB4,”FEBS Lett. 431:102-106.
Garrett et al. (2002) “Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor,”Cell110(6):763-773.
Gill et al. (1984) “Monoclonal Anti-Epidermal Growth Factor Receptor Antibodies Which are Inhibitors of Epidermal Growth Factor Binding and Antagonists of Epidermal Growth Factor Binding and Antagonists of Epidermal Growth Factor-Stimulated Tyrosine Protein Kinase Activity,”J. Biol. Chem. 259:7755-7760.
Hammacher et al. (1996) “The Interluken-6 (IL-6) Partial Antagonist (Q159E,T162P)IL-6 Interacts with the IL-6 Receptor and gp130 but Fails to Induce a Stable Hexameric Receptor Complex,” 271:5464-5473.
Hynes, N.E. (1993) “Amplification and Overexpression of theerbB-2 Gene in Human Tumors: Its Involvement in Tumor Development, Significance as a Prognostic Factor, and Potential as a Target for Cancer Therapy,”Sem. Cancer Biol. 4:19-26.
Jones et al. (1999) “Binding Specificities and Affinities ofefgDomains for ErbB Receptors,”FEBS Lett. 447:227-231.
Kohda et al. (1993) “A 40kDa Epidermal Growth Factor/Transforming Growth Factor α-Binding Domain Produced by Limited Proteolysis of the Extracellular Domain of the Epidermal Growth Factor receptor,”J. Biol. Chem. 268:1976-1981.
Lax et al. (1988) “Chicken Epidermal Growth Factor (EGF) Receptor: cDNA Cloning, Expression in Mouse Cells, and Differential Binding of EGF and Transforming Growth Factor Alpha,”Mol. Cell. Biol. 8:1970-1978.
Maihle et al. (1991) “Native Avian c-erbB Gene Expresses a Secreted Protein Product Corresponding to the Ligand-Binding Domain of the Receptor,”Proc. Natl. Acad. Sci. USA88:1825-1829.
McKern et al. (1997) “Crystallization of the First Three Domains of the Human Insulin-Like Growth Factor-1 Receptor,”Protein Sci. 6:2663-2666.
Minton, A.P. (1994)Modern Analytical Ultracentirfugation: Acquisition and Interpretation of Data for Biological and Synthetic Polymer Systems, Schuster et al. eds., Birkhauser, Boston, p. 81.
Morton et al. (1998) “Kinetic Analysis of Macromolecular Interactions Using Surface Plasmon Resonance Biosensors,”Methods Enzymol295:268-294.
Nice et al. (1999) “Instrumental Biosensors: New Perspectives for the Analysis of Biomolecular Interactions,”BioEssays21:339-352.
Nice et al. (1994) “Synergies Between Micropreparative High-Performance Liquid Chromatography and an Instrumental Optical Biosensor,”J. Chromatogr. A660:169-185.
Norrander et al. (1983) “Construction of Improved M13 Vectors Using Oligodeoxynucleotide-Directed Mutagenesis,”Gene26:101-106.
Prewett et al. (1998) “Mouse-Human Chimeric Anti-Epidermal Growth Factor Receptor Antibody C225 Inhibits the Growth of Humna Renal Cell Carcinoma Xenografts n Nude Mice,”Clin. Cancer Res. 4:2957-2966.
Reiter et al. (1996) “A 1.8kb Alternative Transcript from the Human Epidermal Growth Factor Receptor Gene Encodes a Truncated Form of the Receptor,”Nuc. Acids Res. 24:4050-4056.
Reiter et al. (2001) “Comparative Genomic Sequence Analysis and Isolation of Human and Mouse Alternative EGFR Transcripts Encoding Truncated Receptor Isoforms,”Genomic71:1-20.
Rockwell (1997) “Cell-Surface Perturbations of the Epidermal Growth Factor and Vascular Endothelial Growth Factor Receptors by Phosphorothioate Oligodeoxynucleotides,”Proc. Natl. Acad. Sci. USA94:6523-6528.
Sandgreen et al. (1990) “Overexpression of TGFα in Transgenic Mice: Induction of Epithelial Hyperplasia, Pancreatic Metaplasia, and Carcinoma of the Breast,”Cell61:1121-1135.
Sanger et al. (1977) “DNA Sequencing With Chain-Terminating Inhibitors,”Proc. Natl. Acad. Sci. 74:5463-5467.
Saxon et al. (1999) “Mutagenesis Reveals a Role for Epidermal Growth Factor Receptor Extracellular Subdomain IV in Ligand Binding,”J. Biol. Chem. 274:28356-28362.
Souriau et al. (1997) “A Simple Luciferase Assay for Signal Transduction Activity Detection of Epidermal Growth Factor Displayed on Phage,”Nuc. Acids Res. 25:1585-1590.
Stanley, P. (1989) “Chinese Hamster Ovary Cell Mutants with Multiple Glycosylation Defects for Production of Glycoproteins with Minimal Carbohydrate Heterogeneity,”Mol. Cell. Biol. 9:377-383.
Ullrich et al. (1984) “Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells,”Nature309:418-425.
Vo

Affiliated with

Also associated with

Rating

Truncated EGF receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Truncated EGF receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated EGF receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4020491